About this raise

Who Should Be Interested:
Are you, or is someone in your life, impacted by Alzheimer’s? Is so, Neurotez Inc. could be the investment you’ve been looking for. Their highly experienced team is developing a drug to treat Leptin deficiency in Alzheimer’s patients and/or act as a preventative for those who are at risk, and their drug might just be the missing piece needed to help fight this terrible disease.

The Company:
Neurotez Inc. is on a mission to become the world leaders in biotechnology and to help Alzheimer’s patients with drugs that are both safe and efficacious. Their primary goal is to develop a Leptin product as an innovative hormone replacement therapy for Alzheimer’s disease and/or as a preventative for those who are at risk. Today’s medications provide limited relief, and current efforts, which focus on removing either Abeta or tau deposits from the brain, have not generated any effective drugs for the last 18 years. Neurotez is here to change that -- by focusing on Leptin instead and attacking the disease in a new way. So far, Neurotez has been nominated as the Most Promising Private Company in 2015 by the Biotechnology Industry Organization, as well as a 2010 Incubator Company to Watch at the NJTC Gala Awards. Add in that their team has deep experience and success with thousands of publications in Alzheimer’s, and you can see why Neurotez might just be the Alzheimer's weapon we’ve been waiting for.

The Bottom Line:
Neurotez Inc. is changing the game when it comes to treating and fighting Alzheimer’s. Their Leptin product attacks the disease in a new way, and with Alzheimer’s affecting more than five million Americans and 18 million patients worldwide, we need all the help we can get. This innovative treatment might be just what patients need to help with -- or prevent -- the devastating effects of Alzheimer’s.

Expand

Investment Overview

Invested this round: $95,809

Deal Terms

Total Commitments

Platform
Netcapital
Start Date
01/03/2018
Close Date
02/26/2018
Min. Goal
$10,000
Max Goal
$107,000
Min. Investment

$1

Security Type

Equity - Common

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$1.00

Pre-Money Valuation

$24,544,690

Company & Team

Company

Year Founded
2005
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Location
Bridgewater, New Jersey
Company Website
Visit Website

Team

Employees
11
Founder Name
Nikolaos Tezapsidis
Title
CEO

Financials

Financials are not currently available for this company. This may occur if the company is still Testing the Waters, is a Regulation D offering, or if the financials are still under review and being confirmed by our team. For Reg CF and Reg A+ raises, please check back later.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Company Funding & Growth

Funding history

Close Date Platform Valuation Total Raised Security Type Status Reg Type
01/27/2023 Netcapital $45,272,228 $15,952 Equity - Common Funded RegCF
03/10/2022 StartEngine $44,870,036 $33,845 Equity - Common Funded RegCF
06/24/2021 Netcapital $21,959,058 $255,718 Equity - Common Funded RegCF
02/26/2018 Netcapital $24,544,690 $95,809 Equity - Common Funded RegCF
Create a free account today to gain access to Kingscrowd analytics.

Growth Charts

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Neurotez on NetCapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $24,544,690
Price per Share: $1.00

Follow company

Follow Neurotez on NetCapital

Buy Neurotez's Deal Report

Warning: according to the close date for this deal, Neurotez may no longer be accepting investments.

Neurotez Deal Report

Get Kingscrowd's comprehensive report on Neurotez including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Neurotez is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Neurotez deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge